To Wednesday 03 October 2018
The 9th Santorini Conference aims to answer:
- Can genetic screening help identify individuals at greatest risk for cardio-metabolic diseases and cancer?
- What is the greatest clinical need with regard to diagnosis, prediction and patient stratification for these pathologies and how this is/can be addressed?
- Does a genetic risk score identify patients at highest risk and is its use justified in clinical practice?
- What are the challenges of the current clinical trials?
- What about comorbidities with aging?
- What is the impact of pharmacogenomics on:
- Deliverance of more predictable responses to drug therapy
- Minimisation of the occurrence and severity of adverse drug reactions
- Conduction of more cost-effective clinical trials
- Drug discovery and the drug development process
- Do the existing diagnostic tools answer the needs of pharmacogenomics?
You can already note the dates (30 September to 3 October 2018) on your calendar and plan to join us and help make this 9th event a real success.
For more information about registration and abstracts’ submission please visit the website: www.santoriniconference.org.